Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 4/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5441547 | 0.94 | PTPN7 (0.47) | PTPN7CNR2KCNA5PDE10AMET | |
| SCHEMBL5444330 | 0.92 | PDE10A (0.44) | PTPN7CNR2KCNA5PDE10ANR3C1 | |
| SCHEMBL5448149 | 0.92 | MET (0.40) | PTPN7CNR2PDE10AMET | |
| SCHEMBL14412060 | 0.91 | PTPN7 (0.46) | PTPN7CNR2METL3MBTL1 | |
| SCHEMBL5440849 | 0.91 | CNR2 (0.40) | PTPN7CNR2KCNA5PDE10ASLC2A1 | |
| SCHEMBL5451975 | 0.91 | PTPN7 (0.46) | PTPN7CNR2PDE10AMETALDH1A1 | |
| SCHEMBL5444227 | 0.89 | PTPN7 (0.44) | PTPN7CNR2METALDH1A1L3MBTL1 | |
| SCHEMBL14411428 | 0.89 | CNR2 (0.40) | PTPN7CNR2PDE10ANR3C1MEN1 | |
| SCHEMBL5446369 | 0.86 | PTPN7 (0.44) | PTPN7CNR2KCNA5ALDH1A1 | |
| SCHEMBL5455433 | 0.86 | PDE10A (0.51) | PTPN7CNR2KCNA5PDE10AMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | PTPN7 592/4885CNR2 106/4885KCNA5 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.